Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Prostatic Neoplasms 5Breast Neoplasms 5Sarcoma 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Carcinoma, Renal Cell 3Wilms Tumor 2Unspecified Adult Solid Tumor, Protocol Specific 2Testicular Neoplasms 2Teratoma 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Kidney Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Ovarian Epithelial 2Burkitt Lymphoma 2Breast Neoplasms, Male 2Astrocytoma 2

Interventions

Doxorubicin 4pazopanib 2cixutumumab 2Radiotherapy 2Ifosfamide 2sapanisertib 1romidepsin 1peposertib 1pembrolizumab 1pegfilgrastim 1liposomal doxorubicin 1ixabepilone 1interferon gamma-1b 1Trastuzumab 1Temozolomide 1Specimen Handling 1Sorafenib 1Radiation 1Molecular Diagnostic Techniques 1Microarray Analysis 1Magnetic Resonance Spectroscopy 1Interferon-gamma 1Imatinib Mesylate 1HhAntag691 1Filgrastim 1Everolimus 1Etoposide 1Diathermy 1Biopsy 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sarcoma, Synovial × ixabepilone × Clear all
NCT00331643 2014-11-14

Ixabepilone in Treating Young Patients With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
120 enrolled
CNSGenitourinarySarcoma

Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡